Phase 3
Completed N=123
A Study of Subcutaneous At Home Administration of Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2-positive (HER2+) Early Breast Cancer (eBC)
Source: ClinicalTrials.gov NCT01926886 ↗Enrolled (actual)
123
Serious AEs
7.9%
Results posted
Sep 2019
Primary outcomePrimary: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 90.1; 7.9 percentage of participants
◆ Published Evidence
Established
42citations · ~7 / year
Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer.
Summary
This single arm, multicenter study will evaluate the safety of assisted subcutaneous administration of trastuzumab in participants with HER2+ eBC. Participants who have completed the first 6 cycles of intravenous (IV) trastuzumab as part of the (neo)adjuvant treatment will be eligible to receive a further 12 cycles of trastuzumab in this study. Participants will receive IV trastuzumab at initial loading dose of 8 milligrams per kilogram (mg/kg) body weight (BW) for three-weekly (q3w) regimen and then recommended maintenance dose of 6 mg/kg BW q3w for the first 3 cycles (cycles 7-9) in hospital followed by subcutaneous (SC) administration of trastuzumab at a fixed dose of 600 mg q3w for next 3 cycles (Cycles 10-12) at hospital and SC administration of trastuzumab at a fixed dose of 600 mg q3w at home for the next 6 cycles (Cycles 13-18).
Linked Publications
-
Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) |
90.1; 7.9 | — |
| SECONDARY Number of Participants With Modalities Assessed Using Patient Satisfaction Questionnaire 1 (PSQ1): In-Hospital |
0; 4; 8; 22; 49; 0 | — |
| SECONDARY Number of Participants With Modalities Assessed Using Patient Satisfaction Questionnaire 2 (PSQ2): At Home |
0; 3; 8; 28; 34; 7 | — |
| SECONDARY Participant-reported Severity of Symptoms as Assessed by Monroe Dunaway Anderson Symptom Inventory (MDASI) Questionnaire |
1.79; 3.76; 0.82; 3.01; 1.99; 1.59 | — |
| SECONDARY Participant-reported Interference of Symptoms With Life as Assessed by MDASI Questionnaire |
2.77; 2.11; 3.22; 1.54; 3.34; 2.51 | — |
| SECONDARY Number of Participants With Modalities Assessed Using Patient Experience Questionnaires (PEX) - Part 1:In-Hospital |
87; 0; 0; 0; 15; 87 | — |
| SECONDARY Number of Participants With Modalities Assessed Using PEX - Part 2: At Home |
0; 5; 77; 20; 65; 17 | — |
| SECONDARY Number of Health Care Professionals With Modalities Assessed Using Health Care Professional Questionnaire (HCPEX-1) |
0; 0; 19; 2; 0; 6 | — |
| SECONDARY Disease-Free Survival (DFS) as Assessed by Routine Clinical, Radiological and Laboratory Criteria |
NA | — |
Eligibility Criteria
Inclusion Criteria
- Histologically confirmed non-metastatic primary invasive adenocarcinoma of the breast
- HER2-positive disease immunohistochemistry (IHC)3+ or in situ hybridization (ISH) positive, in line with local reimbursement criteria and determined in a local laboratory that is experienced/certified in HER2-expression testing using an accurate and validated assay
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Hormonal therapy will be allowed as per institutional guidelines
- Left ventricular ejection fraction (LVEF) of greater than or equal to (>/=) 50% measured by echocardiography (ECHO) or multiple gated acquisition (MUGA) scan prior to first dose of trastuzumab SC, or, for those who were receiving trastuzumab when beginning the study, documented results within an acceptable limit from a cardiac assessment within 3 months prior to enrollment
- Participants have completed the first 6 cycles of trastuzumab IV as part of the (neo)adjuvant treatment
- No evidence of residual, locally recurrent or metastatic disease after completion of surgery and chemotherapy, (neo-adjuvant or adjuvant)
- Use of concurrent curative radiotherapy will be permitted
Exclusion Criteria
- History of other malignancy which could affect compliance with the protocol or interpretation of results. Participants with curatively treated carcinoma in situ of the cervix or basal cell carcinoma, and patients with other curatively treated malignancies who have been disease-free for at least 5 years, are eligible
- Participants with severe dyspnea at rest or requiring supplementary oxygen therapy
- Participants with other concurrent serious diseases that may interfere with planned treatment, including severe pulmonary conditions/illness
- Serious cardiac illness or medical conditions that would preclude the use of trastuzumab, specifically: history of documented congestive heart failure (CHF), high-risk uncontrolled arrhythmias, angina pectoris requiring medication, clinically significant valvular disease, evidence of transmural infarction on electrocardiogram (ECG), diagnosed poorly controlled hypertension
- Known infection with human immunodeficiency virus (HIV), active hepatitis B virus (HBV) or hepatitis C virus (HCV)
- Pregnant or lactating women
- Women of childbearing potential and male participants with partners of childbearing potential who are unable or unwilling to use adequate contraceptive measures during study treatment
- Concurrent enrollment in another clinical trial using an investigational anti-cancer treatment, including hormonal therapy, bisphosphonate therapy and immunotherapy, within 28 days prior to the first dose of study treatment
- Known hypersensitivity to trastuzumab, murine proteins, to any of the excipients of Herceptin including hyaluronidase, or the adhesive of the SC device, or a history of severe allergic or immunological reactions, e.g. difficult to control asthma
- Inadequate bone marrow, hepatic or renal function
Data sourced from ClinicalTrials.gov (NCT01926886) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.